Literature DB >> 19215715

Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.

P Kramarz1, Dominique Monnet, A Nicoll, C Yilmaz, B Ciancio.   

Abstract

Variable levels of oseltamivir resistance among seasonal influenza A(H1N1) isolates have been reported in Europe during the 2007-8 northern Hemisphere influenza season. It has been questioned whether oseltamivir use could have driven the emergence and predominance of resistant viruses. This study aimed at describing the levels of use of oseltamivir in 12 European Union (EU) Member States and European Economic Area (EEA)/European Free Trade Area (EFTA) countries. The data were converted into prescription rates and compared with the national proportions of resistant influenza A(H1N1) viruses through regression analysis. Overall use of oseltamivir in European countries between 2002 and 2007 was low compared to e.g. the use in Japan. High variability between the countries and over time was observed. In eight of the 12 countries, there was a peak of prescriptions in 2005, coinciding with concerns about a perceived threat from an influenza pandemic which might have lead to personal stockpiling. Ecological comparison between national levels of use of oseltamivir in 2007 and the proportions of A(H1N1) viruses that were resistant to oseltamivir showed no statistical association. In conclusion, our results do not support the hypothesis that the emergence and persistence of these viruses in 2007-8 was related to the levels of use of oseltamivir in Europe. Further investigation is needed to elucidate the reasons for different level of use between the countries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19215715     DOI: 10.2807/ese.14.05.19112-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  37 in total

1.  Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.

Authors:  Nicole M Bouvier; Saad Rahmat; Natalie Pica
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses.

Authors:  Teridah Ernala Ginting; Kyoko Shinya; Yukihiro Kyan; Akiko Makino; Naomi Matsumoto; Satoko Kaneda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  The global spread of drug-resistant influenza.

Authors:  Dennis L Chao; Jesse D Bloom; Beth F Kochin; Rustom Antia; Ira M Longini
Journal:  J R Soc Interface       Date:  2011-08-24       Impact factor: 4.118

4.  The evolutionary consequences of alternative types of imperfect vaccines.

Authors:  Krisztian Magori; Andrew W Park
Journal:  J Math Biol       Date:  2013-02-28       Impact factor: 2.259

5.  Genital herpes in Canada: Deciphering the hidden epidemic.

Authors:  Mubeen Aslam; Rhonda Y Kropp; Gayatri Jayaraman; Katherine Dinner; Thomas Wong; Marc Steben
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

6.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

7.  Influenza virus resistance to neuraminidase inhibitors: implications for treatment.

Authors:  Shivanjali Shankaran; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

8.  A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.

Authors:  Yoko Matsuzaki; Katsumi Mizuta; Yoko Aoki; Asuka Suto; Chieko Abiko; Kanako Sanjoh; Kanetsu Sugawara; Emi Takashita; Tsutomu Itagaki; Yuriko Katsushima; Makoto Ujike; Masatsugu Obuchi; Takato Odagiri; Masato Tashiro
Journal:  Virol J       Date:  2010-03-05       Impact factor: 4.099

Review 9.  Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Authors:  Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

10.  Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus.

Authors:  David M Hartley; Noele P Nelson; Eli N Perencevich
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.